3-氨基吡啶-2-甲酸乙酯 | 27507-15-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基吡啶-2-甲酸乙酯
• 中文别名: 3-氨基吡啶-2-羧酸乙酯
• 英文名称: ethyl 3-aminopyridine-2-carboxylate
• 英文别名: ethyl 3-aminopicolinate；3-amino-2-ethoxycarbonylpyridine；3-aminopyridine-2-carboxylic acid ethyl ester
• CAS: 27507-15-9
• 化学式: C₈H₁₀N₂O₂
• mdl: MFCD00661294
• 分子量: 166.18
• InChiKey: FKDRDUIRSZRBSN-UHFFFAOYSA-N

物化性质

• 熔点：
  131-133 °C
• 沸点：
  326.2±22.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Aminopyridine-2-carboxylic acid ethyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Aminopyridine-2-carboxylic acid ethyl ester
CAS number: 27507-15-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H10N2O2
Molecular weight: 166.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基吡啶-2-甲酸乙酯 在 sodium hydroxide 、 盐酸羟胺 作用下， 以 甲醇 、 水 为溶剂， 反应 48.0h， 以90%的产率得到3-氨基-N-羟基-2-吡啶甲酰胺
  参考文献：
  名称：

  3-羟基-4-氧代-3,4-二氢-5-氮杂苯并1,2,3-三氮烯†

  摘要：

  已知但长期以来被忽视的化合物HODhat在某些情况下是有用的肽偶联添加剂。内置于系统中的HODhat铀盐和phospho盐也是有用的独立偶联剂。与相关添加剂和偶联剂的比较表明，在逐步偶联和链段偶联的情况下，新系统有时比先前描述的系统更有效，有时效率更低。装配十肽ACP模型的应用表明，在某些条件下，HDATU比HDTU更有效，并且比HATU更有效。

  DOI：

  10.1021/jo030017a
• 作为产物：
  描述：

  乙醇 、 3-氨基吡啶-2-羧酸 在 硫酸 作用下， 以 乙醇 为溶剂， 以76 %的产率得到3-氨基吡啶-2-甲酸乙酯
  参考文献：
  名称：

  发现 MK-8189，一种用于治疗精神分裂症的高效选择性 PDE10A 抑制剂

  摘要：

  PDE10A 是纹状体信号传导的重要调节因子，当受到抑制时，可以使功能失调的活动正常化。鉴于精神分裂症涉及纹状体活动功能障碍，PDE10A 抑制代表了一种潜在的新治疗方法。以开发 PDE10A 抑制剂为目标，通过合理设计对片段进行早期优化，产生了一系列有效的嘧啶 PDE10A 抑制剂，需要在理化性质、脱靶活性和药代动力学方面进一步改进。在此，我们描述了异构嘧啶系列的发现，该系列解决了早期化合物的缺陷，并导致了化合物18 (MK-8189) 的发明，该化合物目前处于治疗精神分裂症的 2b 期临床开发阶段。

  DOI：

  10.1021/acs.jmedchem.2c01521

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090018114A1

  公开（公告）日：2009-01-15

  The present application relates to cannabinoid receptor ligands containing compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式(I)化合物的大麻素受体配体，其中A、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL
  申请人：PFIZER

  公开号：WO2016097918A1

  公开（公告）日：2016-06-23

  Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  公式(I)的化合物： (I) 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。
• The transformations of 4-heteroarylaminomethylene-5(4<i>H</i>)-oxazolones into dehydropeptide derivatives
  作者：Mateja Aljaẑ-Roẑiĉ、Jurij Svete、Branko Stanovnik

  DOI：10.1002/jhet.5570320533

  日期：1995.9

  2-Phenyl-4-heteroarylaminomethylene-5(4H)-oxazolones 3, which were prepared from the corresponding N,N-dimethyl-N'-heteroarylformamidines 1 and hippuric acid 2 in acetic anhydride, react with amino acids giving dehydropeptide derivatives 4, 5, and 6 as products. Dehydration of N-protected peptides 7–10, containing glycine at the C-terminal, followed by the reaction with formamidines 1 gave 2-subst

  2-苯基-4- heteroarylaminomethylene-5（4 ħ）-oxazolones 3，其由相应的制备N，N-二甲基N” -heteroarylformamidines 1和马尿酸2在乙酸酐中，与氨基酸给予dehydropeptide衍生物反应4 ，5和6作为产品。脱水的N保护肽7-10，在C端含有甘氨酸，然后与甲form 1反应，得到2-取代的-4-杂芳基氨基亚甲基-5（4 H）-恶唑酮11-14。
• SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210188845A1

  公开（公告）日：2021-06-24

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR 6 or N; Y is CR 3 or N; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了Formula (I)的化合物： 或其盐，其中：X为CR 6 或N；Y为CR 3 或N；R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 和m在此处定义。还揭示了使用这些化合物来抑制二酰甘油激酶α（DGKα）和二酰甘油激酶ζ（DGKζ）中的一个或两个活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面是有用的。
• NITROGEN CONTAINING HETEROARYL COMPOUNDS
  申请人：Bleicher Konrad

  公开号：US20110306589A1

  公开（公告）日：2011-12-15

  The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.

  这项发明涉及一种新颖的含氮杂环芳基化合物，其化学式为（I），其中A1、A2、R1、R2、R3、R4、R5和R6如描述和索赔中所定义，并且其生理上可接受的盐和酯。这些化合物抑制PDE10A并可用作治疗药物。